Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 - DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien

The Myotonic Dystrophy market is expected to accelerate through 2036, according to DelveInsight’s report “Myotonic Dystrophy Market Insights, Epidemiology, and Market Forecast-2036,” which tracks the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan. The report estimates the market was worth about USD 89 million in 2023 and projects growth with a 18.4% CAGR over 2022–2036. It also cites that by July 2026, about 41% of patients with congenital myotonic dystrophy require hospitalization within a 12-month period. In the regulatory pipeline, AMO Pharma plans to use hospitalization as the primary efficacy endpoint in the registrational study of AMO-02, with support involving three major regulatory agencies. Separately, the U.S. FDA placed a partial clinical hold on the FREEDOM2-DM1 trial in March 2026 over preclinical pharmacology and toxicology concerns, and Avidity Biosciences said final Phase 1/2 MARINA results for delpacibart etedesiran (del-desiran) will be published in the Feb. 19, 2025 issue of The New England Journal of Medicine.